Prospective study of the G20210A polymorphism in the prothrombin gene, plasma prothrombin concentration, and incidence of venous thromboembolism

Am J Hematol. 2002 Dec;71(4):285-90. doi: 10.1002/ajh.10229.

Abstract

Case-control studies have indicated increased risk of venous thrombosis associated with the prothrombin gene G20210A polymorphism and with elevated plasma prothrombin levels. We sought to confirm these results in a prospective population-based study of 21,690 persons. We measured G20210A and prothrombin antigen on pre-event blood samples of 302 participants who developed venous thromboembolism (VTE) and 626 participants who remained free of VTE. Approximately 4.0% of cases and 2.4% of controls carried the G20210A polymorphism, but only one of 137 African Americans did. The odds ratio in whites was 1.87 (95% CI = 0.85, 4.11)--higher for those who reported a prior history of VTE (OR = 5.44) than those reporting no VTE history (OR = 1.41) and in those with idiopathic VTE (OR = 2.51) than those with secondary VTE (OR = 1.38). There was no association between venous thromboembolism and plasma prothrombin antigen level. We estimated that the G20210A polymorphism may account for approximately 2.5% of venous thromboembolism events in United States whites.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Age Factors
  • Aged
  • Black People / genetics
  • Black or African American
  • Case-Control Studies
  • Genotype
  • Humans
  • Incidence
  • Middle Aged
  • Odds Ratio
  • Polymorphism, Single Nucleotide / genetics*
  • Prospective Studies
  • Prothrombin / genetics*
  • Prothrombin / metabolism*
  • Recurrence
  • Research Design
  • Risk Factors
  • Thromboembolism / epidemiology*
  • Thromboembolism / genetics*
  • United States / epidemiology
  • White People / genetics

Substances

  • Prothrombin